(Q39341953)

11 September 2017

title

High-intensity focused ultrasound tumor ablation activates autologous tumor-specific cytotoxic T lymphocytes (English)

1 reference

11 September 2017

0 references

Ji-Zhu Xia

1

1 reference

11 September 2017

Fang-Lin Xie

2

1 reference

11 September 2017

Li-Feng Ran

3

1 reference

11 September 2017

Xun-Peng Xie

4

1 reference

11 September 2017

Yan-Min Fan

5

1 reference

11 September 2017

Feng Wu

6

1 reference

11 September 2017

publication date

24 May 2012

1 reference

Ultrasound in Medicine and Biology

11 September 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

11 September 2017

volume

38

1 reference

11 September 2017

issue

8

1 reference

11 September 2017

page(s)

1363-1371

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

11 September 2017

1 reference

Cancer immunotherapy: a treatment for the masses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

Multimodal approaches to the treatment of hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

Technologies for ablation of hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

Technology insight: High-intensity focused ultrasound for urologic cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

Cell death mechanisms induced by cytotoxic lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

Role of acoustic cavitation in the delivery and monitoring of cancer treatment by high-intensity focused ultrasound (HIFU).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

In situ tumor ablation creates an antigen source for the generation of antitumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

Minimally invasive treatment of malignant hepatic tumors: at the threshold of a major breakthrough

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

Radiofrequency ablation induces antigen-presenting cell infiltration and amplification of weak tumor-induced immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

Activation and dramatically increased cytolytic activity of tumor specific T lymphocytes after radio-frequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

Release of endogenous danger signals from HIFU-treated tumor cells and their stimulatory effects on APCs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

Investigation of HIFU-induced anti-tumor immunity in a murine tumor model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

In vitro effect of focused ultrasound or thermal stress on HSP70 expression and cell viability in three tumor cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

The safety and feasibility of extracorporeal high-intensity focused ultrasound (HIFU) for the treatment of liver and kidney tumours in a Western population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

A plasmid DNA vaccine encoding the extracellular domain of porcine endoglin induces anti-tumour immune response against self-endoglin-related angiogenesis in two liver cancer models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

Immune monitoring of T-cell responses in cancer vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

High-intensity focused ultrasound in the treatment of solid tumours.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

Treatment of uterine leiomyosarcoma in a xenograft nude mouse model using high-intensity focused ultrasound: a potential treatment modality for recurrent pelvic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

Adoptive T cell therapy of solid cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

Response to sublethal heat treatment of prostatic tumor cells and of prostatic tumor infiltrating T-cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

Short-duration-focused ultrasound stimulation of Hsp70 expression in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

Analysis of clinical effect of high-intensity focused ultrasound on liver cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

Roles of heat-shock proteins in antigen presentation and cross-presentation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

Increased infiltration of activated tumor-infiltrating lymphocytes after high intensity focused ultrasound ablation of human breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

Regulation of heat shock protein 27 expression of prostatic cells in response to heat treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

Transcatheter chemoembolization of unresectable hepatocellular carcinoma: current knowledge and future directions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

Immunotherapy for liver tumors: present status and future prospects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

Liver tumor ablation: percutaneous and open approaches

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

Global cancer statistics, 2002

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

Heat shock proteins as regulators of the immune response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

Strategies for the management of hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

In-vitro activation of cytotoxic T lymphocytes by fusion of mouse hepatocellular carcinoma cells and lymphotactin gene-modified dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

Image-guided percutaneous ablation therapies for hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

Therapeutic applications of ultrasound

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

Monitoring of antigen-specific cytolytic T lymphocytes in cancer patients receiving immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

Extracorporeal high intensity focused ultrasound ablation in the treatment of patients with large hepatocellular carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

Activated anti-tumor immunity in cancer patients after high intensity focused ultrasound ablation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

Advanced hepatocellular carcinoma: treatment with high-intensity focused ultrasound ablation combined with transcatheter arterial embolization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

Extracorporeal high intensity focused ultrasound in the treatment of patients with solid malignancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

Host antitumour immune responses to HIFU ablation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

Expression of tumor antigens and heat-shock protein 70 in breast cancer cells after high-intensity focused ultrasound ablation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

The effect of high intensity focused ultrasound treatment on metastases in a murine melanoma model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

Adoptive T-cell therapy of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

Changes in circulating immunosuppressive cytokine levels of cancer patients after high intensity focused ultrasound treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ULTRASMEDBIO.2012.03.009

10.1016/J.ULTRASMEDBIO.2012.03.009

7 January 2021

Identifiers

DOI

1 reference

11 September 2017

1 reference